Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | XDH | P47989 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8012633 | 0.84 | KDM4E (0.33) | KDM4EMAPTALDH1A1GAALMNA | |
| SCHEMBL8079826 | 0.68 | — | — | |
| SCHEMBL6797038 | 0.67 | JAK2 (0.33) | — | |
| SCHEMBL1627470 | 0.61 | PI4KA (0.31) | LMNAXDH | |
| SCHEMBL9377776 | 0.59 | — | — | |
| SCHEMBL19916984 | 0.58 | PI4KA (0.35) | KDM4EMAPTALDH1A1GAALMNA | |
| SCHEMBL22048110 | 0.57 | MEN1 (0.38) | KDM4EMAPTALDH1A1GAALMNA | |
| SCHEMBL19941773 | 0.55 | RAB9A (0.46) | KDM4EMAPTALDH1A1GAALMNA | |
| SCHEMBL7529443 | 0.54 | MEN1 (0.36) | KDM4EMAPTALDH1A1GAALMNA | |
| SCHEMBL2116843 | 0.54 | PDPK1 (0.33) | KDM4EMAPTALDH1A1GAALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009120358-A1 | OLIGOMER-NITROGENOUS BASE CONJUGATES | NEKTAR THERAPEUTICS (US) | 2009-10-01 | — | — | WO | claimed |
| US-6060463-A | Treatment of conditions of abnormally increased intraocular pressure by administration of phosphonylmethoxyalkyl nucleoside analogs and related nucleoside analogs | Freeman, William (US) | 2000-05-09 | — | — | US | claimed |
| US-5869468-A | Treatment of conditions of abnormally increased intraocular pressure by administration of phosphonylmethoxyalkyl nucleoside analogs and related nucleoside analogs | FREEMAN WILLIAM R (US) | 1999-02-09 | — | — | US | claimed |
| US-5641763-A | N-phosphonylmethoxyalkyl derivatives of pyrimdine and purine bases and a therapeutical composition therefrom with antiviral activity | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY OF THE ACADEMY OF SCIENCES OF THE CZECH REPUBLIC (CZ) | 1997-06-24 | — | — | US | claimed |
| EP-0754046-A1 | USE OF PHOSPHONYLMETHOXYALKYL NUCLEOSIDES FOR THE TREATMENT OF RAISED INTRAOCULAR PRESSURE | FREEMAN, William R. (US) | 1997-01-22 | — | — | EP | claimed |
| WO-1995026734-A1 | USE OF PHOSPHONYLMETHOXYALKYL NUCLEOSIDES FOR THE TREATMENT OF RAISED INTRAOCULAR PRESSURE | FREEMAN WILLIAM R (US) | 1995-10-12 | — | — | WO | claimed |
| US-5142051-A | Viricides special for mutants of herpes viruses | CESKOSLOVENSKA AKADEMIE VED (CS) | 1992-08-25 | — | — | US | claimed |
| EP-0253412-B1 | N-PHOSPHONYLMETHOXYALKYL DERIVATIVES OF PYRIMIDINE AND PURINE BASES, METHODS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS THEREFROM WITH ANTIVIRAL ACTIVITY | Ceskoslovenska akademie ved (CS) | 1990-10-31 | — | — | EP | claimed |
| EP-0253412-A2 | N-Phosphonylmethoxyalkyl derivatives of pyrimidine and purine bases, methods for their preparation and pharmaceutical compositions therefrom with antiviral activity | Ceskoslovenska akademie ved (CS) | 1988-01-20 | — | — | EP | claimed |
| EP-2846788-A1 | USE OF COMPOUNDS FOR THE TREATMENT OF PAIN | Akron Molecules AG (AT) | 2015-03-18 | — | — | EP | disclosed |
| WO-2013167743-A1 | USE OF COMPOUNDS FOR THE TREATMENT OF PAIN | AKRON MOLECULES GMBH (AT) | 2013-11-14 | — | — | WO | disclosed |
| US-20110059921-A1 | Oligomer-Nitrogenous Base Conjugates | Ektar Therapeutics (US) | 2011-03-10 | — | — | US | disclosed |
| US-20100137240-A1 | USE OF NUCLEOSIDE DERIVATIVES AS ANTI-KOI HERPES VIRUS IN FISH | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2010-06-03 | — | — | US | disclosed |
| EP-2155210-A2 | USE OF NUCLEOSIDE DERIVATIVES AS ANTI-KOI HERPES VIRUS IN FISH | Katholieke Universiteit Leuven (BE) | 2010-02-24 | — | — | EP | disclosed |
| US-6060463-A | Treatment of conditions of abnormally increased intraocular pressure by administration of phosphonylmethoxyalkyl nucleoside analogs and related nucleoside analogs | Freeman, William (US) | 2000-05-09 | — | — | US | disclosed |
| US-5869468-A | Treatment of conditions of abnormally increased intraocular pressure by administration of phosphonylmethoxyalkyl nucleoside analogs and related nucleoside analogs | FREEMAN WILLIAM R (US) | 1999-02-09 | — | — | US | disclosed |
| EP-0754046-A1 | USE OF PHOSPHONYLMETHOXYALKYL NUCLEOSIDES FOR THE TREATMENT OF RAISED INTRAOCULAR PRESSURE | FREEMAN, William R. (US) | 1997-01-22 | — | — | EP | disclosed |
| WO-1995026734-A1 | USE OF PHOSPHONYLMETHOXYALKYL NUCLEOSIDES FOR THE TREATMENT OF RAISED INTRAOCULAR PRESSURE | FREEMAN WILLIAM R (US) | 1995-10-12 | — | — | WO | disclosed |
| EP-0253412-B1 | N-PHOSPHONYLMETHOXYALKYL DERIVATIVES OF PYRIMIDINE AND PURINE BASES, METHODS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS THEREFROM WITH ANTIVIRAL ACTIVITY | Ceskoslovenska akademie ved (CS) | 1990-10-31 | — | — | EP | disclosed |
| EP-0253412-A2 | N-Phosphonylmethoxyalkyl derivatives of pyrimidine and purine bases, methods for their preparation and pharmaceutical compositions therefrom with antiviral activity | Ceskoslovenska akademie ved (CS) | 1988-01-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110059921-A1 | Oligomer-Nitrogenous Base Conjugates | NCL, NMBR, SLC43A3 | KDM4E 4731/4885MAPT 196/4885ALDH1A1 3033/4885 |
| US-20100137240-A1 | USE OF NUCLEOSIDE DERIVATIVES AS ANTI-KOI HERPES VIRUS IN FISH | TK1, PIGO, NME1 | KDM4E 95/4885MAPT 3419/4885ALDH1A1 3998/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.